Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma

Martín-Liberal, Juan; Perez, Ezequiel Cayetano; Muro, Xavier García del

doi:10.1080/13543784.2019.1555236

Cited by 8 publications

(4 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These trials have revealed significant response rates, which can be attributed, at least in part, to the suppression of the FUS-CHOP transcription factor [ 119 ]. Ongoing Phase II trial investigations are being conducted to explore the phenomenon of locally relapsed uterine leiomyosarcoma [ 120 , 121 ] as well as soft-tissue sarcomas [ 122 ], with a focus on clinical development and evaluation.…”

Section: Tunicatesmentioning

confidence: 99%

Marine-Derived Anticancer Agents Targeting Apoptotic Pathways: Exploring the Depths for Novel Cancer Therapies

Dalisay,

Tenebro,

Sabido

et al. 2024

Marine Drugs

View full text Add to dashboard Cite

Extensive research has been conducted on the isolation and study of bioactive compounds derived from marine sources. Several natural products have demonstrated potential as inducers of apoptosis and are currently under investigation in clinical trials. These marine-derived compounds selectively interact with extrinsic and intrinsic apoptotic pathways using a variety of molecular mechanisms, resulting in cell shrinkage, chromatin condensation, cytoplasmic blebs, apoptotic bodies, and phagocytosis by adjacent parenchymal cells, neoplastic cells, or macrophages. Numerous marine-derived compounds are currently undergoing rigorous examination for their potential application in cancer therapy. This review examines a total of 21 marine-derived compounds, along with their synthetic derivatives, sourced from marine organisms such as sponges, corals, tunicates, mollusks, ascidians, algae, cyanobacteria, fungi, and actinobacteria. These compounds are currently undergoing preclinical and clinical trials to evaluate their potential as apoptosis inducers for the treatment of different types of cancer. This review further examined the compound’s properties and mode of action, preclinical investigations, clinical trial studies on single or combination therapy, and the prospective development of marine-derived anticancer therapies.

show abstract

Section: Tunicatesmentioning

confidence: 99%

Marine-Derived Anticancer Agents Targeting Apoptotic Pathways: Exploring the Depths for Novel Cancer Therapies

Dalisay,

Tenebro,

Sabido

et al. 2024

Marine Drugs

View full text Add to dashboard Cite

show abstract

“…Tivozanib activity has been also investigated in hepatocellular carcinoma in association with durvalumab [78] and in recurrent, platinum-resistant ovarian cancer, fallopian tube cancer, and primary peritoneal cancer [79,80]. Tivozanib has been studied in phase I and II clinical trials as monotherapy and in combination with other drugs for the treatment of STS [81], glioblastoma [82], breast [83], and colorectal cancers, and other advanced gastrointestinal cancers [84,85].…”

Section: Tivozanibmentioning

confidence: 99%

Diarylureas as Antitumor Agents

et al. 2021

View full text Add to dashboard Cite

The diarylurea is a scaffold of great importance in medicinal chemistry as it is present in numerous heterocyclic compounds with antithrombotic, antimalarial, antibacterial, and anti-inflammatory properties. Some diarylureas, serine-threonine kinase or tyrosine kinase inhibitors, were recently reported in literature. The first to come into the market as an anticancer agent was sorafenib, followed by some others. In this review, we survey progress over the past 10 years in the development of new diarylureas as anticancer agents.

show abstract

“…Liposarcomas and intimal sarcomas form distinct STS subset, where MDM2 and CDK4 gene amplifications serve as oncogenic drivers as well as therapeutic targets [24]. Low molecular weight inhibitors were described for both genes, in particular, CDK4 inhibitor palbociclib is currently involved in clinical trials [25], and experimental MDM2 inhibitor demonstrated anticancer activity in vitro and in vivo [26].…”

Section: Not Describedmentioning

confidence: 99%

Current Approaches for Personalized Therapy of Soft Tissue Sarcomas

Кирсанов

Lesovaya

Fetisov

et al. 2020

Sarcoma

View full text Add to dashboard Cite

Soft tissue sarcomas (STS) are a highly heterogeneous group of cancers of mesenchymal origin with diverse morphologies and clinical behaviors. While surgical resection is the standard treatment for primary STS, advanced and metastatic STS patients are not eligible for surgery. Systemic treatments, including standard chemotherapy and newer chemical agents, still play the most relevant role in the management of the disease. Discovery of specific genetic alterations in distinct STS subtypes allowed better understanding of mechanisms driving their pathogenesis and treatment optimization. This review focuses on the available targeted drugs or drug combinations based on genetic aberration involved in STS development including chromosomal translocations, oncogenic mutations, gene amplifications, and their perspectives in STS treatment. Furthermore, in this review, we discuss the possible use of chemotherapy sensitivity and resistance assays (CSRA) for the adjustment of treatment for individual patients. In summary, current trends in personalized management of advanced and metastatic STS are based on combination of both genetic testing and CSRA.

show abstract

Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma

Cited by 8 publications

References 96 publications

Marine-Derived Anticancer Agents Targeting Apoptotic Pathways: Exploring the Depths for Novel Cancer Therapies

Marine-Derived Anticancer Agents Targeting Apoptotic Pathways: Exploring the Depths for Novel Cancer Therapies

Diarylureas as Antitumor Agents

Current Approaches for Personalized Therapy of Soft Tissue Sarcomas

Contact Info

Product

Resources

About